Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4325-4332

  Pederson, Lee C ^a,b   Buchsbaum, Donald J ^b   Vickers, Selwyn M ^a   Kancharla, Sreekanth R ^b   Mayo, Matthew S ^c   Curiel, David T ^c   Stackhouse, Murray A ^b  

^a UAB Department of Surgery   (United States)

^b NONE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; RADIOSENSITIZING AGENT; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAM THERAPY; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GENE THERAPY; HELA CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; TUMOR VOLUME; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; CYTOSINE DEAMINASE; FLUOROURACIL; GAMMA RAYS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NUCLEOSIDE DEAMINASES; PRODRUGS; PROMOTER REGIONS (GENETICS); RADIATION-SENSITIZING AGENTS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030817590     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Schoenthaler, R., Castro, J. R., Halberg, F. E., and Phillips, T. L. Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons. Int. J. Radiat. Oncol. Biol. Phys., 27: 75-82, 1993.
2. Mittal, B., Duetsch, M., and Iwatsuki, S. Primary cancers of extrahepatic biliary passages. Int. J. Radiat. Oncol. Biol. Phys., 11: 849-854, 1985.
3. Pitt, H., Dooley, W., Yeo, C., and Cameron, J. L. Malignancies of the biliary tree. Curr. Prob. Surg., 32: 1-100, 1995.
4. Pitt, H. A., Nakeeb, A., Abrams, R. A., Coleman, J., Piantadosi, S., Yeo, C. A., Lillemoe, K. D., and Cameron, J. L. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann. Surg., 221: 788-798, 1995.
5. Vauthey, J. N., and Blumgart, L. H. Recent advances in the management of cholangiocarcinomas. Semin. Liver Dis., 14: 109-114, 1994.
6. Nimura, Y., Kamiya, J., Kondo, S., Nagino, M., and Kanai, M. Technique of inserting multiple biliary drains and management. Hepatogastroenterology, 42: 323-331, 1995.
7. Kubota, Y., Nakatani, S., Nakahashi, Y., Takaoka, M., Kin, H., and Inoue, K. Bilateral internal biliary drainage of hilar cholangiocarcinoma with modified Gianturco Z stents inserted via a single percutaneous tract. J. Vasc. Interv. Radiol., 4: 605-610, 1993.
8. Wagner, H. J., Vakil, N., and Knyrim, K. Improved biliary stenting using a balloon catheter and the combined technique for difficult stenoses. Gastrointest. Endosc., 39: 688-693, 1993.
9. Saunders, K., Longmire, W., Tomkins, R., Chavez, M., Cates, J., and Roslyn, J. Diffuse bile duct tumors: guidelines for management. Am. Surg., 57: 816-820, 1991.
10. Yeo, C. J., Pitt, H. A., and Cameron, J. L. Cholangiocarcinoma. Surg. Clin. North Am., 70: 1429-1447, 1990.
11. Van Der Hul, R. L., Plaisier, P. W., Lameris, J. S., Veeze-Kuijpers, B., Van Blankenstein, M., and Terpstra, O. T. Proximal cholangiocarcinoma: a multidisciplinary approach. Eur. J. Surg., 160: 213-218, 1994.
12. Hsue, V., Wong, C. S., Moore, M., Erlichman, C., Cummings, B. J., and MacLeod, M. A Phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Int. J. Radiat. Phys., 34: 445-450, 1996.
13. Brady, L. W., Markoe, A. M., Micaily, B., Fisher, S. A., and Lamm, F. R. Innovative techniques in radiation oncology, clinical research programs to improve local and regional control in cancer. Cancer (Phila.), 65: 610-624, 1990.
14. Veeze-Kuijpers, B., Meerwaldt, J. H., Lameris, J. S., Van Blankenstein, M., Van Putten, W. L. J., and Terpstra, O. T. The role of radiotherapy in the treatment of bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 18: 63-67, 1990.
15. Gonzalez Gonzalez, D., Gerard, J. P., Maners, A. W., De La Lande-Guyaux, B., Van Dijk-Milatz, A., Meerwaldt, J. H., Bosset, J. F., and Van Dijk, J. D. P. Results of radiation therapy in carcinoma of the proximal bile duct (klatskin tumor). Semin. Liver Dis., 10: 131-141, 1990.
16. Kuvshinoff, B. W., Armstrong, J. G., Fong, Y., Schupak, K., Getradjman, G., Heffernan, N., and Blumgart, L. H. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br. J. Surg., 82: 1522-1525, 1995.
17. Verbeek, P. C. M., Van Leeuwen, D. J., Van Der Heyde, M. N., and Gonzalez Gonzalez, D. Does additive radiotherapy after hilar resection improve survival of cholangiocarcinoma? An analysis of sixty-four patients. Ann. Chir., 45: 350-354, 1991.
18. Saunders, K. D., Tomkins, R. K., Cates, J. A., Longmire, W. P., and Roslyn, J. J. The natural history of carcinoma of the bile duct in patients less than forty-five years of age. Surg. Gynecol. Obstet., 174: 1-6, 1992.
19. Busse, P. M., Stone, M. D., Sheldon, T. A., Chaffey, J. T., Cady, B., McDermott, W. V., Bothe, A., Jenkins, R., and Steele, G. Intraoperative radiation therapy for biliary tract carcinoma: resulls of a 5-year experience. Surgery, 105: 724-733, 1989.
20. Freeman, S. M., Whartenbury, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A. J. In situ use of suicide genes for cancer therapy. Semin. Oncol., 23: 31-45, 1996.
21. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
22. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91: 8302-8306, 1994.
23. Wills, K. N., Huang, W., Harris, M. P., Machemer, T., Maneval, D. C., and Gregory, R. J. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-medialed transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther., 2; 191-197, 1995.
24. McKie, E. A., MacLean, A. R., Lewis, A. D., Cruickshank, G., Rampling, R., Barnett, S. C., Kennedy, P. G. E., and Brown, S. M. Selective in vitro replication of herpes simplex virus type I (HSV-1) icp34.5 null mutants in primary human CNS tumors: evaluation of a potentially effective clinical therapy. Br. J. Cancer, 74: 745-752, 1996.
25. Wei, K., and Huber, B. E. Cytosine deaminase gene as a positive selection marker. J. Biol. Chem., 271: 3812-3816, 1996.
26. Hoganson, D. K., Batra, R. K., Olsen, J. C., and Boucher, R. C. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res., 56: 1315-1323, 1996.
27. Harris, J. D., Gutierrez, A. A., Hurst, H. C., Sikora, K., and Lemoine, N. R. Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther., 1: 170-175, 1994.
28. Austin, E. A., and Huber, B. E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol., 43: 380-387, 1992.
29. Mullen, C. Metabolic suicide genes in gene therapy. Pharmacol. Ther., 63: 199-207, 1994.
30. Chen, S., Li Chen, X. H., Kosai, K., Finegold, M. J., Rich, S., and Woo, S. L. C. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA, 92: 2577-2581, 1995.
31. Yang, L., Hwang, R., Pandit, L., Gordon, E. M., Anderson, W. F., and Parekh, D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg., 224: 405-417, 1996.
32. Rowley, S., Lindauer, M., Gebert, J. F., Haberkorn, U., Oberdorfer F., Moebius, U., Herfarth, C., and Schackert, H. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer. J. Surg. Oncol., 61: 42-48, 1996.
33. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
34. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme prodrug systems in a human colorectal cell line. Cancer Res., 55: 4808-4812, 1995.
35. Ohwada, A., Hirschowitz, E. A., and Crystal, R. G. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Human Gene Ther., 7: 1567-1576, 1996.
36. Mullen, C. A., Coale, M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506, 1994.
37. Khil, M. S., Kim, J. H., Mullen, C. A., Kim, S. H., and Freytag, S. O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma in culture transduced with cytosine deaminase gene. Clin. Cancer Res., 2: 53-57, 1996.
38. Richards, C. A., Austin, E. A., and Huber, B. E. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Human Gene Ther., 6: 881-893, 1995.
39. Kanai, F., Lan, K., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., Hamada, H., Nakabayashi, H., Tamaoki, T., and Omata, M. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res., 57: 461-465, 1997.
40. Sougawa, M., Akagi, K., Murata, T., Kawasaki, S., Sawada, S., Yoshii, G., and Tanaka, Y. Enhancement of radiation effects by acyclovir. Int. J. Radiat. Oncol. Biol. Phys., 12: 1537-1540, 1986.
41. Kim, J. H., Kim, S. H., Brown, S. L., and Freytag, S. O. Selective enhancement by antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res., 54: 6035-6056, 1994.
42. Kim, J. H., Kim, S. H., Kolozsvary, A., Brown, S. L., Kim, O. B., and Freytag, S. O. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 91 gliosarcoma cells in vitro and in vivo by antiviral agents. Int. J. Radiat. Oncol. Biol. Phys., 33: 861-868, 1995.
43. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Human Gene Ther., 8: 73-85, 1997.
44. Rosenfeld, M. E., Feng, M., Michael, S. I., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian cells to ganciclovir. Clin. Cancer Res., 1: 1571-1580, 1995.
45. Becker, T. C., Noel, R. J., Coats, W. S., Gomez-Foix, A. M., Alam, T., Gerard, R. D., and Newgard, C. B. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol., 43: 161-188, 1994.
46. Haberkorn, U., Oberdorfer, F., Gebert, J., Morr, I., Haack, K., Weber, K., Lindauer, M., van Kaick, G., and Schackert, H. K. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated 5-fluorocytosine. J. Nucl. Med., 37: 87-94, 1996.
47. Fertil, B., Dertinger, H., Courdi, A., and Malaise, E. P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat. Res., 99: 73-84, 1984.
48. Klatskin, G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatitis: an unusual tumor with distinctive clinical and pathological features. Am. J. Med., 38: 241-256, 1965.
49. Vickers, S. M., Phillips, J. O., Bynon, J. S., Thompson, J. A., and Curiel, D. T. In vivo gene transfer to the human biliary tract. Gene Ther., 3: 825-828, 1996.
50. Harvey, J. H., Smith, F. P., and Schein, P. S. 5-Fluorouracil, mitomycin, and doxorubicin (fam) in carcinoma of the biliary tract. J. Clin. Oncol., 2: 1245-1248, 1984.
51. Tsubono, M., Nio, Y., Tseng, C. C., Kawabata, K., Masai, Y., Hayashi, H., Fukumoto, M., and Tobe, T. Experimental chemotherapy for xenograft cell lines of human bile duct and gallbladder cancers in nude mice. J. Surg. Oncol., 51: 274-280, 1992.
52. Sifton, D. W. (ed.). Physicians Desk Reference, pp. 2079-2080. Montvale, NJ: Medical Economics Co., 1996.
53. Gallardo, D., Drazen, K. E., and McBride, W. H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res., 56: 4891-4893, 1996.
54. Yamagishi, N., Miyakoshi, J., Ohtsu, S., Day, R. S., and Takebe, H. Modification of the radiosensitivily of human cells to which simian virus 40 T-antigen was transfected. J. Radiat. Res., 36: 239-247, 1995.
55. Kruglikov, I. L. What does the mean inactivation dose characterize? Radiat. Res., 133: 391-392, 1993.
56. Fertil, B., and Malaise, E. P. The mean inactivation dose: experimental versus theoretical. Radiat. Res., 108: 222-225, 1986.